CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures

Alyaa M. Abdel-Haleem, Ellen Casavant, Balazs Toth, Edmond Teng, Cecilia Monteiro, Nikhil J. Pandya, Casper C. Hoogenraad, Brad A. Friedman, Felix L. Yeh, Veronica G. Anania, Gloriia Novikova
doi: https://doi.org/10.1101/2024.04.11.24305670

Article usage

Article usage: April 2024 to November 2024

AbstractFullPdf
Apr 20241911785
May 2024551151
Jun 2024291810
Jul 202440621
Aug 202422139
Sep 202429931
Oct 202439940
Nov 202432228
Back to top
Posted April 12, 2024.
Download PDF

Supplementary Material

Data/Code
Email
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures
Alyaa M. Abdel-Haleem, Ellen Casavant, Balazs Toth, Edmond Teng, Cecilia Monteiro, Nikhil J. Pandya, Casper C. Hoogenraad, Brad A. Friedman, Felix L. Yeh, Veronica G. Anania, Gloriia Novikova
medRxiv 2024.04.11.24305670; doi: https://doi.org/10.1101/2024.04.11.24305670
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area